New research from the CWMH.
We are very pleased to announce the release of the MGH Perinatal Depression Scale available free of charge on the App Store (https://appsto.re/us/-3X4jb.i). The MGHPDS smartphone app includes digital versions of perinatal depression screening tools [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression. SAGE-547, now called brexanolone, is a new type of antidepressant: a formulation of allopregnanolone, which is [...]
While we use lithium less commonly now than we have in the past, lithium is still one of the very best mood stabilizers we have. And with regard to its reproductive safety, we have [...]
Massachusetts General Hospital Efficacy Study Centers on EnBrace HR™ SUNSET, LA (PRWEB) OCTOBER 18, 2016: JayMac Pharmaceuticals is sponsoring a study at Massachusetts General Hospital to assess the efficacy of a pre-and post-natal supplement, EnBrace [...]
The use of the newer “atypical” or second-generation antipsychotic agents continues to increase. These medications are used to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and anxiety disorders. Although [...]
Despite the increasing use of the newer “atypical” or second-generation antipsychotic agents to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders, we have relatively little data [...]
Despite the increasing use of the newer “atypical” or second-generation antipsychotic agents to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders, we have relatively little data [...]
Dyslipidemia is a common side effect of atypical antipsychotics and, for a significant number of patients, may limit the acceptabillily of this class of drugs as an option for long-term treatment. This open trial tested [...]
Several recent articles indicate that the burden of menopausal symptoms is greater than generally perceived. About 80% of women experience vasomotor symptoms (VMS) – hot flashes and night sweats — as they transition into the [...]
In healthy perimenopausal women with hot flashes, treatment with both estradiol and venlafaxine resulted in significantly greater improvement in quality of life, as compared to placebo. Estradiol had beneficial treatment effects on all domains of the [...]
